Clinical trialNCT06321536RecruitingPhase 2Interventional

Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)

SponsorEmory UniversityEnrollment60Multi-Drug Resistant Organism Colonization

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Michael Woodworth, MD
Emory University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

A.G Rhodes Wesley Woods
Atlanta, Georgia, United States
Recruiting
Emory Long Term Acute Care (ltac)
Decatur, Georgia, United States
Recruiting
Rml Specialty Hospital
Hinsdale, Illinois, United States
Recruiting
Penn Medicine Rittenhouse
Philadelphia, Pennsylvania, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Allogeneic Microbiota in Glycerol

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Jan 2025
Primary completion: 31 Jul 2026
Completion: 31 Dec 2026
Last update posted: 5 Nov 2025
Registered enrollment: 60
Registry id: NCT06321536

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.